Human EPCAM PicoKine ELISA Kit
- Known as:
- Human EPCAM PicoKine Enzyme-linked immunosorbent assay test Kit
- Catalog number:
- EK0755
- Product Quantity:
- 1x96 well plate
- Category:
- -
- Supplier:
- boster immunoleader
- Gene target:
- Human EPCAM PicoKine ELISA Kit
Related genes to: Human EPCAM PicoKine ELISA Kit
- Gene:
- EPCAM NIH gene
- Name:
- epithelial cell adhesion molecule
- Previous symbol:
- M4S1, MIC18, TACSTD1
- Synonyms:
- Ly74, TROP1, GA733-2, EGP34, EGP40, EGP-2, KSA, CD326, Ep-CAM, HEA125, KS1/4, MK-1, MH99, MOC31, 323/A3, 17-1A, TACST-1, CO-17A, ESA
- Chromosome:
- 2p21
- Locus Type:
- gene with protein product
- Date approved:
- 1995-10-02
- Date modifiied:
- 2019-04-23
Related products to: Human EPCAM PicoKine ELISA Kit
Related articles to: Human EPCAM PicoKine ELISA Kit
- The cell surface protein of EpCAM (Epithelial Cell Adhesion Molecule), also known as CD326, is generally expressed in normal epithelia; whereas, its upregulation has been reported in certain tissue stem cells, precursors, and a number of epithelium-derived tumors. EpCAM was initially introduced as a transmembrane glycoprotein modulating cell-cell adhesion and facilitating epithelial-specific intercellular cell adhesion. However, its recognized functions have expanded to include diverse roles in fundamental cellular processes, such as the regulation of proliferation, differentiation, cell migration, and cell signaling. The aim of the current review is to unravel the mechanisms by which EpCAM controls the initiation of cancer through interactions and the formation of a complex with Wnt pathway molecules; also, to summarize and discuss the original data obtained from international research laboratories on the properties of EpCAM, including its expression in human CSCs (Cancer Stem Cells) and CTCs (Circulating Tumor Cells). Questions such as how this property led to this molecule being considered as a modulator of epithelial plasticity or phenotypic flexibility rather than a true structural adhesion molecule that mdiates mechanical cell-cell adhesion, are also addressed. This review provides the significance of EpCAM-based identification in liquid biopsy and describes the main complications and challenges in its clinical applications for targeted therapeutic approaches. We also discuss new insights on EpCAM-targeted therapeutic approaches, including monoclonal antibodies, CAR-T cells, and bispecific antibodies. In conclusion, we discuss future research directions in which EpCAM targeting could contribute to further progress in cancer diagnosis, prognosis, and treatment. - Source: PubMed
Publication date: 2026/05/25
Ghari MehrzadGhaemimanesh Fatemeh - Longitudinal monitoring of tumor progression and metastasis provides significant benefits to improve the treatment outcome of breast cancer. Matrix metalloproteinase 14 (MMP14) on extracellular vesicles (EVs) is highly relevant to tumor invasiveness, yet the sensitivity and specificity of detection are hindered by tremendous amounts of normal EVs amidst complex blood samples. Here we developed an ultrafast one-step dual-target orthogonal barcoding-based microscale thermophoretic extracellular vesicle (DOT-EV) assay to evaluate MMP14 levels on tumor-derived EVs (T-EVs). Leveraging the orthogonal barcoding of two allosteric aptamer probes targeting MMP14 and EpCAM, our assay specifically recognizes signals from MMP14 of tumor EVs and enhances the accuracy of clinical diagnosis. The microscale thermophoresis induces convection flow and accelerates DNA assembly on EVs, enabling ultrafast one-step detection of T-EV MMP14 within just 20 s, consuming 10 μL plasma samples. The T-EV MMP14 profiling on metastatic mouse models and patient samples of breast cancer demonstrated that the DOT-EV assay can monitor different development stages of the tumor and predict metastatic potential. Notably, triple-negative breast cancer was successfully differentiated from other subtypes. The DOT-EV assay offers a pioneering tool for noninvasive and precise diagnosis, progression monitoring, and metastasis prediction of cancer, showing great promise in advancing the clinical implementation of precision medicine. - Source: PubMed
Publication date: 2026/06/03
Chen AipengWang RuokeZou YanDing YueTian RuitingWang YuqingLan FangzhouWu QiaoyiZhang PengFang XiaoniYang Chaoyong - Germline testing is underutilized and varies by cancer diagnosis. We hypothesized that patient and clinician involvement in cascade testing of relatives varies by the cancer susceptibility (breast gastrointestinal [GI]) of the affected gene. - Source: PubMed
Publication date: 2026/06/03
Kurian Allison WAbrahamse PaulFurgal AllisonVeenstra Christine MCourser Rebecca RHofer Timothy PHodan RachelCaswell-Jin Jennifer LGomez Scarlett LWard Kevin CHamilton Ann SLiu LihuaAn Lawrence CKatz Steven J - Molecular adhesion plays a central role in many biological systems, yet existing methods to quantify adhesive strength often struggle to bridge the gap between single-molecule resolution and biologically relevant environments. Here, we present a scalable micromagnetic bead-based adhesion assay capable of quantifying detachment forces under physiologically meaningful conditions. Designed to probe mucoadhesion in the context of mucociliary clearance, our system applies controlled magnetic forces to ligand-coated beads adhered to functionalized substrates and tracks detachment events using high-speed microscopy and calibrated z-displacement mapping. The platform combines control of substrate and bead surface chemistry with high-throughput imaging and in situ force calibration via Stokes drag. We demonstrate the ability to distinguish sub-nanonewton to nanonewton force regimes across a range of bead-substrate pairings, including carboxyl-carboxyl, polyethylene glycol-polyethylene glycol, and cell culture-derived human bronchial epithelial mucus interactions. Surface functionalization was validated via fluorescence imaging and zeta potential measurements, while detachment forces were used to estimate binding energy and infer dissociation constants. This assay enables detailed characterization of multivalent, force-sensitive adhesive interactions and offers a powerful new approach to studying bioadhesive systems, including mucus-pathogen interactions and drug delivery materials. - Source: PubMed
Cribb Jeremy AFazelpour FarnazWollensak David ARice DanielledeJong MaxHill DavidSuperfine Richard - Hepatocellular carcinoma (HCC) is one of the leading causes of tumour-related death. T cells and cytokines play a critical role in tumour progression, but the T cell landscape correlated with HCC prognosis remains undepicted. - Source: PubMed
Cui GuangzuHu EryaPeng QingpingZhou XinZhao YuLiu HaicongWang XinwenChen YihongShen HongZeng ShanMa Jiayao